RAFAEL GUERRERO: Open Payments
NPI 1386600138 · KATY, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,239 in 174 payments from 20 companies in 2025. Trend: 2023 $3,136 · 2024 $3,157 · 2025 $4,239
Food & beverage: $4,174Education: $65
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $764 |
| Otsuka America Pharmaceutical, Inc. | 18 | $608 |
| Neurocrine BioSciences, Inc. | 12 | $366 |
| ABBVIE INC. | 23 | $333 |
| Alkermes, Inc. | 10 | $251 |
| Axsome Therapeutics, Inc. | 6 | $226 |
| HARMONY BIOSCIENCES LLC | 5 | $213 |
| Lundbeck LLC | 9 | $205 |
| E.R. Squibb & Sons, L.L.C. | 7 | $196 |
| Vanda Pharmaceuticals Inc. | 9 | $193 |
Products named: CAPLYTA, REXULTI, INGREZZA, VRAYLAR, ARISTADA, COBENFY, FANAPT, ABILIFY ASIMTUFII.
Industry payments across TX — which companies pay providers there.
